Stereotaxis adds Shifrin, Holm to senior exec team

Stereotaxis has appointed Kevin Shifrin, as Stereotaxis’ new senior vice president of global marketing and business development; and Magnus Holm, PhD, as the new general manager for Europe.

Both Shifrin and Holm will report to Michael P. Kaminski, president and chief operating officer, according to the company.

Shifrin joins Stereotaxis from C.R. Bard, a developer, manufacturer and marketer of healthcare products in the fields of vascular, urology, oncology and surgical specialty products, where he served as vice president of global marketing for the peripheral vascular division.  He joined Bard in 2002 from Cordis, a subsidiary of Johnson & Johnson, where he served as the executive director of Marketing for Cordis Cardiology Europe, and helped oversee the execution of European marketing programs supporting the Cordis stent business. 

Holm joins Stereotaxis from Biosense Webster, a leader in technological advancements for the diagnosis and treatment of cardiac arrhythmias, where he served most recently as vice president of Europe, Middle East and Asia (EMEA), responsible for sales and marketing and business development throughout the EMEA region.

Around the web

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services.